Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Mark Douglas SmithDirector | Jazz PharmaceuticalsJAZZ | Open-market sale10b5-1 plan | 06/15 | 06/17 | 1,157 sh | $230.55 | $266,746.35 | −10.7% |
Patil Neena M.EVP & Chief Legal Officer | Jazz PharmaceuticalsJAZZ | Open-market sale10b5-1 plan | 06/10 | 06/12 | 1,200 sh | $231.83 | $278,196 | −2.3% |
Cozadd Bruce C.Director | Jazz PharmaceuticalsJAZZ | Open-market sale10b5-1 plan | 06/01 | 06/03 | 6,000 sh | $235.12 | $1,410,720 | −1.6% |
Patil Neena M.EVP & Chief Legal Officer | Jazz PharmaceuticalsJAZZ | Open-market sale10b5-1 plan | 05/28 | 06/01 | 1,192 sh | $236.97 | $282,468.24 | −2.2% |
Samantha PearceEVP, Chief Commercial Officer | Jazz PharmaceuticalsJAZZ | Open-market sale | 05/28 | 06/01 | 6,907 sh | $235.41 | $1,625,976.87 | −12.1% |
Rick E. WinninghamDirector | Jazz PharmaceuticalsJAZZ | Open-market sale | 05/22 | 05/27 | 2,741 sh | $241.57 | $662,143.37 | −22.3% |
Heather Ann McSharryDirector | Jazz PharmaceuticalsJAZZ | Open-market sale | 05/22 | 05/27 | 2,000 sh | $241.00 | $482,000 | −9.8% |
Cozadd Bruce C.Director | Jazz PharmaceuticalsJAZZ | Open-market sale10b5-1 plan | 05/01 | 05/05 | 6,000 sh | $203.33 | $1,219,980 | −1.6% |
Jazz PharmaceuticalsJAZZ | Open-market sale10b5-1 plan | 04/01 | 04/03 | 6,000 sh3 trades | $190.50avg. | $1,143,006.72 | −1.5% | |
Carr PatriciaSVP, Chief Accounting Officer | Jazz PharmaceuticalsJAZZ | Open-market sale | 03/09 | 03/09 | 1,287 sh | $182.94 | $235,443.78 | −16.5% |
Jazz PharmaceuticalsJAZZ | Open-market sale10b5-1 plan | 03/03 | 03/04 | 6,000 sh3 trades | $186.44avg. | $1,118,616.87 | −1.5% | |
Norbert G. RiedelDirector | Jazz PharmaceuticalsJAZZ | Open-market sale | 02/27 | 03/02 | 3,415 sh | $192.00 | $655,680 | −32.7% |
Jazz PharmaceuticalsJAZZ | Open-market sale | 02/26–02/27 | 03/02 | 2,370 sh2 trades | $192.60avg. | $456,466.3 | −20.4% | |
Jazz PharmaceuticalsJAZZ | Open-market sale | 02/26 | 03/02 | 55,600 sh11 trades | $191.56avg. | $10,650,568.29 | −48.6% | |
Henderson Mary ElizabethSVP, Technical Operations | Jazz PharmaceuticalsJAZZ | Open-market sale | 02/26 | 03/02 | 5,343 sh | $194.49 | $1,039,160.07 | −15.7% |
Henderson Mary ElizabethSVP, Technical Operations | Jazz PharmaceuticalsJAZZ | Open-market sale | 25/12/09 | 25/12/11 | 2,238 sh | $169.51 | $379,363.38 | −10.3% |
Jazz PharmaceuticalsJAZZ | Open-market sale | 25/12/05 | 25/12/09 | 4,660 sh2 trades | $171.20avg. | $797,777.6 | −39.9% | |
Jazz PharmaceuticalsJAZZ | Open-market sale | 25/11/26 | 25/12/01 | 77,500 sh4 trades | $177.81avg. | $13,780,212.17 | −16.5% | |
Heather Ann McSharryDirector | Jazz PharmaceuticalsJAZZ | Open-market sale | 25/11/20 | 25/11/24 | 3,415 sh | $177.78 | $607,118.7 | −14.3% |
Jazz PharmaceuticalsJAZZ | Open-market sale | 25/11/18 | 25/11/20 | 18,000 sh4 trades | $181.09avg. | $3,259,530.69 | −4.4% |